Research programme: biodefence therapeutic - Navigen/University of Utah

Drug Profile

Research programme: biodefence therapeutic - Navigen/University of Utah

Alternative Names: Slit2N

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator University of Utah
  • Developer Navigen Pharmaceuticals
  • Class Proteins
  • Mechanism of Action Cadherin 5 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Systemic inflammatory response syndrome

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Systemic-inflammatory-response-syndrome in USA (Parenteral)
  • 08 Dec 2010 Early research in Systemic inflammatory response syndrome in viral haemorrhagic fevers or anthrax infection in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top